nodes	percent_of_prediction	percent_of_DWPC	metapath
Alosetron—CYP1A2—chronic obstructive pulmonary disease	0.441	1	CbGaD
Alosetron—CYP2E1—Aminophylline—chronic obstructive pulmonary disease	0.0767	0.203	CbGbCtD
Alosetron—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.047	0.124	CbGbCtD
Alosetron—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.047	0.124	CbGbCtD
Alosetron—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0443	0.117	CbGbCtD
Alosetron—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.036	0.0952	CbGbCtD
Alosetron—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0356	0.0941	CbGbCtD
Alosetron—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0244	0.0643	CbGbCtD
Alosetron—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0232	0.0614	CbGbCtD
Alosetron—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0207	0.0547	CbGbCtD
Alosetron—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0121	0.0321	CbGbCtD
Alosetron—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0115	0.0303	CbGbCtD
Alosetron—Ondansetron—CYP1A2—chronic obstructive pulmonary disease	0.00269	1	CrCbGaD
Alosetron—CYP1A2—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00169	0.0504	CbGpPWpGaD
Alosetron—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00147	0.044	CbGpPWpGaD
Alosetron—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.0013	0.0389	CbGpPWpGaD
Alosetron—HTR3A—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.00126	0.0377	CbGpPWpGaD
Alosetron—HTR3A—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.00112	0.0336	CbGpPWpGaD
Alosetron—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00106	0.0318	CbGpPWpGaD
Alosetron—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.000737	0.022	CbGpPWpGaD
Alosetron—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.000684	0.0204	CbGpPWpGaD
Alosetron—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.00067	0.02	CbGpPWpGaD
Alosetron—Ill-defined disorder—Roflumilast—chronic obstructive pulmonary disease	0.000606	0.00419	CcSEcCtD
Alosetron—CYP2E1—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000602	0.018	CbGpPWpGaD
Alosetron—Eczema—Montelukast—chronic obstructive pulmonary disease	0.0006	0.00415	CcSEcCtD
Alosetron—Injury—Formoterol—chronic obstructive pulmonary disease	0.000599	0.00414	CcSEcCtD
Alosetron—Injury—Arformoterol—chronic obstructive pulmonary disease	0.000599	0.00414	CcSEcCtD
Alosetron—Malaise—Roflumilast—chronic obstructive pulmonary disease	0.000589	0.00408	CcSEcCtD
Alosetron—Injury—Montelukast—chronic obstructive pulmonary disease	0.000587	0.00406	CcSEcCtD
Alosetron—Gastroenteritis—Salbutamol—chronic obstructive pulmonary disease	0.000587	0.00406	CcSEcCtD
Alosetron—Eczema—Salbutamol—chronic obstructive pulmonary disease	0.000578	0.004	CcSEcCtD
Alosetron—Injury—Salbutamol—chronic obstructive pulmonary disease	0.000566	0.00391	CcSEcCtD
Alosetron—Hypoglycaemia—Formoterol—chronic obstructive pulmonary disease	0.000564	0.0039	CcSEcCtD
Alosetron—Hypoglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.000564	0.0039	CcSEcCtD
Alosetron—Hyperglycaemia—Aminophylline—chronic obstructive pulmonary disease	0.000564	0.0039	CcSEcCtD
Alosetron—Myalgia—Roflumilast—chronic obstructive pulmonary disease	0.000556	0.00385	CcSEcCtD
Alosetron—Dermatitis atopic—Prednisolone—chronic obstructive pulmonary disease	0.000555	0.00384	CcSEcCtD
Alosetron—Anxiety—Roflumilast—chronic obstructive pulmonary disease	0.000554	0.00383	CcSEcCtD
Alosetron—Discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00055	0.0038	CcSEcCtD
Alosetron—Upper respiratory tract infection—Tiotropium—chronic obstructive pulmonary disease	0.000548	0.00379	CcSEcCtD
Alosetron—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000541	0.0161	CbGpPWpGaD
Alosetron—CYP1A2—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000537	0.016	CbGpPWpGaD
Alosetron—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000535	0.016	CbGpPWpGaD
Alosetron—Hypoglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.000533	0.00369	CcSEcCtD
Alosetron—Hyperglycaemia—Tiotropium—chronic obstructive pulmonary disease	0.000532	0.00368	CcSEcCtD
Alosetron—Infection—Roflumilast—chronic obstructive pulmonary disease	0.00053	0.00366	CcSEcCtD
Alosetron—Skin disorder—Roflumilast—chronic obstructive pulmonary disease	0.000518	0.00358	CcSEcCtD
Alosetron—Urinary tract infection—Tiotropium—chronic obstructive pulmonary disease	0.000511	0.00354	CcSEcCtD
Alosetron—CYP2E1—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000503	0.015	CbGpPWpGaD
Alosetron—Cramp muscle—Formoterol—chronic obstructive pulmonary disease	0.000496	0.00343	CcSEcCtD
Alosetron—Cramp muscle—Arformoterol—chronic obstructive pulmonary disease	0.000496	0.00343	CcSEcCtD
Alosetron—Sinusitis—Tiotropium—chronic obstructive pulmonary disease	0.000493	0.00341	CcSEcCtD
Alosetron—Nasopharyngitis—Formoterol—chronic obstructive pulmonary disease	0.000492	0.00341	CcSEcCtD
Alosetron—Nasopharyngitis—Arformoterol—chronic obstructive pulmonary disease	0.000492	0.00341	CcSEcCtD
Alosetron—Acne—Prednisolone—chronic obstructive pulmonary disease	0.000488	0.00338	CcSEcCtD
Alosetron—Gastritis—Arformoterol—chronic obstructive pulmonary disease	0.000487	0.00337	CcSEcCtD
Alosetron—Gastritis—Formoterol—chronic obstructive pulmonary disease	0.000487	0.00337	CcSEcCtD
Alosetron—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000487	0.0146	CbGpPWpGaD
Alosetron—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.000486	0.00336	CcSEcCtD
Alosetron—Cramp muscle—Montelukast—chronic obstructive pulmonary disease	0.000486	0.00336	CcSEcCtD
Alosetron—CYP2E1—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000484	0.0145	CbGpPWpGaD
Alosetron—Nasopharyngitis—Montelukast—chronic obstructive pulmonary disease	0.000482	0.00334	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Montelukast—chronic obstructive pulmonary disease	0.000476	0.00329	CcSEcCtD
Alosetron—Abdominal pain upper—Salbutamol—chronic obstructive pulmonary disease	0.000475	0.00329	CcSEcCtD
Alosetron—Cramp muscle—Salbutamol—chronic obstructive pulmonary disease	0.000468	0.00324	CcSEcCtD
Alosetron—Nasopharyngitis—Salbutamol—chronic obstructive pulmonary disease	0.000465	0.00322	CcSEcCtD
Alosetron—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.00046	0.00318	CcSEcCtD
Alosetron—CYP1A2—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000457	0.0137	CbGpPWpGaD
Alosetron—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000456	0.00315	CcSEcCtD
Alosetron—Abdominal distension—Salbutamol—chronic obstructive pulmonary disease	0.000452	0.00313	CcSEcCtD
Alosetron—Arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.000447	0.00309	CcSEcCtD
Alosetron—Upper respiratory tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000442	0.00306	CcSEcCtD
Alosetron—Upper respiratory tract infection—Formoterol—chronic obstructive pulmonary disease	0.000442	0.00306	CcSEcCtD
Alosetron—Alopecia—Aminophylline—chronic obstructive pulmonary disease	0.000442	0.00306	CcSEcCtD
Alosetron—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.000439	0.00304	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000439	0.0131	CbGpPWpGaD
Alosetron—CYP2E1—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000437	0.0131	CbGpPWpGaD
Alosetron—Upper respiratory tract infection—Montelukast—chronic obstructive pulmonary disease	0.000433	0.003	CcSEcCtD
Alosetron—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.000429	0.00297	CcSEcCtD
Alosetron—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.000429	0.00297	CcSEcCtD
Alosetron—Urticaria—Roflumilast—chronic obstructive pulmonary disease	0.000424	0.00293	CcSEcCtD
Alosetron—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.000422	0.00292	CcSEcCtD
Alosetron—Upper respiratory tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000418	0.00289	CcSEcCtD
Alosetron—CYP1A2—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000416	0.0124	CbGpPWpGaD
Alosetron—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000414	0.0124	CbGpPWpGaD
Alosetron—Urinary tract infection—Arformoterol—chronic obstructive pulmonary disease	0.000412	0.00285	CcSEcCtD
Alosetron—Urinary tract infection—Formoterol—chronic obstructive pulmonary disease	0.000412	0.00285	CcSEcCtD
Alosetron—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.000408	0.00282	CcSEcCtD
Alosetron—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.000405	0.0028	CcSEcCtD
Alosetron—Jaundice—Montelukast—chronic obstructive pulmonary disease	0.000405	0.0028	CcSEcCtD
Alosetron—Dermatitis atopic—Prednisone—chronic obstructive pulmonary disease	0.000403	0.00279	CcSEcCtD
Alosetron—Sinusitis—Arformoterol—chronic obstructive pulmonary disease	0.000398	0.00275	CcSEcCtD
Alosetron—Sinusitis—Formoterol—chronic obstructive pulmonary disease	0.000398	0.00275	CcSEcCtD
Alosetron—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000393	0.00272	CcSEcCtD
Alosetron—HTR3A—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000391	0.0117	CbGpPWpGaD
Alosetron—Jaundice—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.0027	CcSEcCtD
Alosetron—Sinusitis—Montelukast—chronic obstructive pulmonary disease	0.00039	0.0027	CcSEcCtD
Alosetron—Urinary tract infection—Salbutamol—chronic obstructive pulmonary disease	0.000389	0.00269	CcSEcCtD
Alosetron—Fungal infection—Prednisone—chronic obstructive pulmonary disease	0.000387	0.00267	CcSEcCtD
Alosetron—Sweating—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00266	CcSEcCtD
Alosetron—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.000383	0.00265	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.00038	0.0113	CbGpPWpGaD
Alosetron—Sinusitis—Salbutamol—chronic obstructive pulmonary disease	0.000376	0.0026	CcSEcCtD
Alosetron—Hepatitis—Montelukast—chronic obstructive pulmonary disease	0.000373	0.00258	CcSEcCtD
Alosetron—Hypoaesthesia—Montelukast—chronic obstructive pulmonary disease	0.000371	0.00257	CcSEcCtD
Alosetron—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.00037	0.00256	CcSEcCtD
Alosetron—CYP2E1—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000366	0.0109	CbGpPWpGaD
Alosetron—Haemoglobin—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.0025	CcSEcCtD
Alosetron—Haemorrhage—Salbutamol—chronic obstructive pulmonary disease	0.00036	0.00249	CcSEcCtD
Alosetron—Cough—Tiotropium—chronic obstructive pulmonary disease	0.000359	0.00248	CcSEcCtD
Alosetron—Hypoaesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000358	0.00248	CcSEcCtD
Alosetron—Acne—Prednisone—chronic obstructive pulmonary disease	0.000355	0.00245	CcSEcCtD
Alosetron—Hypertension—Tiotropium—chronic obstructive pulmonary disease	0.000355	0.00245	CcSEcCtD
Alosetron—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000354	0.0106	CbGpPWpGaD
Alosetron—Infection—Aminophylline—chronic obstructive pulmonary disease	0.000353	0.00244	CcSEcCtD
Alosetron—CYP2E1—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000352	0.0105	CbGpPWpGaD
Alosetron—Myalgia—Tiotropium—chronic obstructive pulmonary disease	0.00035	0.00242	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000343	0.0102	CbGpPWpGaD
Alosetron—Contusion—Prednisone—chronic obstructive pulmonary disease	0.000342	0.00237	CcSEcCtD
Alosetron—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.000342	0.00237	CcSEcCtD
Alosetron—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00034	0.0102	CbGpPWpGaD
Alosetron—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.00034	0.00235	CcSEcCtD
Alosetron—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.00034	0.00235	CcSEcCtD
Alosetron—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000339	0.00235	CcSEcCtD
Alosetron—Rash—Roflumilast—chronic obstructive pulmonary disease	0.000336	0.00233	CcSEcCtD
Alosetron—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.000336	0.00232	CcSEcCtD
Alosetron—Headache—Roflumilast—chronic obstructive pulmonary disease	0.000334	0.00231	CcSEcCtD
Alosetron—Infection—Tiotropium—chronic obstructive pulmonary disease	0.000333	0.0023	CcSEcCtD
Alosetron—CYP2E1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000329	0.00983	CbGpPWpGaD
Alosetron—Skin disorder—Tiotropium—chronic obstructive pulmonary disease	0.000326	0.00225	CcSEcCtD
Alosetron—Injury—Prednisolone—chronic obstructive pulmonary disease	0.000324	0.00224	CcSEcCtD
Alosetron—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000321	0.0096	CbGpPWpGaD
Alosetron—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00222	CcSEcCtD
Alosetron—Muscle spasms—Formoterol—chronic obstructive pulmonary disease	0.000319	0.00221	CcSEcCtD
Alosetron—Muscle spasms—Arformoterol—chronic obstructive pulmonary disease	0.000319	0.00221	CcSEcCtD
Alosetron—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000317	0.00219	CcSEcCtD
Alosetron—Ulcer—Prednisone—chronic obstructive pulmonary disease	0.000316	0.00218	CcSEcCtD
Alosetron—Muscle spasms—Montelukast—chronic obstructive pulmonary disease	0.000312	0.00216	CcSEcCtD
Alosetron—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000311	0.00215	CcSEcCtD
Alosetron—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000311	0.00215	CcSEcCtD
Alosetron—CYP1A2—Estrogen Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.00031	0.00927	CbGpPWpGaD
Alosetron—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.000309	0.00213	CcSEcCtD
Alosetron—Ill-defined disorder—Arformoterol—chronic obstructive pulmonary disease	0.000308	0.00213	CcSEcCtD
Alosetron—Ill-defined disorder—Formoterol—chronic obstructive pulmonary disease	0.000308	0.00213	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.000305	0.00211	CcSEcCtD
Alosetron—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000304	0.00211	CcSEcCtD
Alosetron—Muscle spasms—Salbutamol—chronic obstructive pulmonary disease	0.000301	0.00208	CcSEcCtD
Alosetron—Malaise—Arformoterol—chronic obstructive pulmonary disease	0.000299	0.00207	CcSEcCtD
Alosetron—Malaise—Formoterol—chronic obstructive pulmonary disease	0.000299	0.00207	CcSEcCtD
Alosetron—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000293	0.00203	CcSEcCtD
Alosetron—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00029	0.00201	CcSEcCtD
Alosetron—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000289	0.002	CcSEcCtD
Alosetron—Cough—Formoterol—chronic obstructive pulmonary disease	0.000289	0.002	CcSEcCtD
Alosetron—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000287	0.00198	CcSEcCtD
Alosetron—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00198	CcSEcCtD
Alosetron—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00198	CcSEcCtD
Alosetron—Cough—Montelukast—chronic obstructive pulmonary disease	0.000283	0.00196	CcSEcCtD
Alosetron—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000282	0.00195	CcSEcCtD
Alosetron—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000282	0.00195	CcSEcCtD
Alosetron—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000282	0.00195	CcSEcCtD
Alosetron—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000282	0.00195	CcSEcCtD
Alosetron—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000281	0.00195	CcSEcCtD
Alosetron—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000281	0.00195	CcSEcCtD
Alosetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000279	0.00834	CbGpPWpGaD
Alosetron—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000279	0.00193	CcSEcCtD
Alosetron—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000279	0.00193	CcSEcCtD
Alosetron—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000276	0.00191	CcSEcCtD
Alosetron—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00191	CcSEcCtD
Alosetron—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00191	CcSEcCtD
Alosetron—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000276	0.00191	CcSEcCtD
Alosetron—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000273	0.00189	CcSEcCtD
Alosetron—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.00187	CcSEcCtD
Alosetron—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000269	0.00186	CcSEcCtD
Alosetron—Infection—Formoterol—chronic obstructive pulmonary disease	0.000269	0.00186	CcSEcCtD
Alosetron—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000267	0.00184	CcSEcCtD
Alosetron—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000266	0.00184	CcSEcCtD
Alosetron—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000266	0.00184	CcSEcCtD
Alosetron—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000263	0.00182	CcSEcCtD
Alosetron—Infection—Montelukast—chronic obstructive pulmonary disease	0.000263	0.00182	CcSEcCtD
Alosetron—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.000263	0.00182	CcSEcCtD
Alosetron—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.000263	0.00182	CcSEcCtD
Alosetron—CYP1A2—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000263	0.00785	CbGpPWpGaD
Alosetron—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000262	0.00181	CcSEcCtD
Alosetron—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.0018	CcSEcCtD
Alosetron—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000259	0.00179	CcSEcCtD
Alosetron—CYP2E1—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000258	0.00772	CbGpPWpGaD
Alosetron—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000257	0.00178	CcSEcCtD
Alosetron—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000257	0.00768	CbGpPWpGaD
Alosetron—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000254	0.00759	CbGpPWpGaD
Alosetron—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000254	0.00176	CcSEcCtD
Alosetron—CYP1A2—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000252	0.00753	CbGpPWpGaD
Alosetron—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000248	0.00172	CcSEcCtD
Alosetron—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000247	0.00739	CbGpPWpGaD
Alosetron—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000247	0.00171	CcSEcCtD
Alosetron—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000247	0.00171	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00171	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00171	CcSEcCtD
Alosetron—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000243	0.00726	CbGpPWpGaD
Alosetron—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000241	0.00167	CcSEcCtD
Alosetron—CYP1A2—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000239	0.00714	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000238	0.0071	CbGpPWpGaD
Alosetron—Injury—Prednisone—chronic obstructive pulmonary disease	0.000236	0.00163	CcSEcCtD
Alosetron—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000233	0.00697	CbGpPWpGaD
Alosetron—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000233	0.00161	CcSEcCtD
Alosetron—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000233	0.00161	CcSEcCtD
Alosetron—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00161	CcSEcCtD
Alosetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000232	0.00692	CbGpPWpGaD
Alosetron—Pain—Formoterol—chronic obstructive pulmonary disease	0.000231	0.0016	CcSEcCtD
Alosetron—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000231	0.0016	CcSEcCtD
Alosetron—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.0016	CcSEcCtD
Alosetron—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000231	0.0016	CcSEcCtD
Alosetron—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000229	0.00158	CcSEcCtD
Alosetron—Pain—Montelukast—chronic obstructive pulmonary disease	0.000227	0.00157	CcSEcCtD
Alosetron—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000226	0.00156	CcSEcCtD
Alosetron—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000225	0.00671	CbGpPWpGaD
Alosetron—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00155	CcSEcCtD
Alosetron—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000224	0.00155	CcSEcCtD
Alosetron—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000223	0.00154	CcSEcCtD
Alosetron—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000223	0.00154	CcSEcCtD
Alosetron—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000223	0.00154	CcSEcCtD
Alosetron—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.00152	CcSEcCtD
Alosetron—CYP1A2—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00022	0.00656	CbGpPWpGaD
Alosetron—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00151	CcSEcCtD
Alosetron—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000218	0.00151	CcSEcCtD
Alosetron—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000215	0.00149	CcSEcCtD
Alosetron—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000215	0.00149	CcSEcCtD
Alosetron—CYP2E1—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000214	0.00638	CbGpPWpGaD
Alosetron—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000213	0.00147	CcSEcCtD
Alosetron—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.00146	CcSEcCtD
Alosetron—CYP1A2—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000211	0.00631	CbGpPWpGaD
Alosetron—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000211	0.00146	CcSEcCtD
Alosetron—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000211	0.00146	CcSEcCtD
Alosetron—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000211	0.00146	CcSEcCtD
Alosetron—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000211	0.00146	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.00021	0.00628	CbGpPWpGaD
Alosetron—Headache—Tiotropium—chronic obstructive pulmonary disease	0.00021	0.00145	CcSEcCtD
Alosetron—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000209	0.00624	CbGpPWpGaD
Alosetron—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.000207	0.00143	CcSEcCtD
Alosetron—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000206	0.00143	CcSEcCtD
Alosetron—CYP2E1—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000206	0.00616	CbGpPWpGaD
Alosetron—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000203	0.0014	CcSEcCtD
Alosetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000203	0.00606	CbGpPWpGaD
Alosetron—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000199	0.00138	CcSEcCtD
Alosetron—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000199	0.00138	CcSEcCtD
Alosetron—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000199	0.00138	CcSEcCtD
Alosetron—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000195	0.00135	CcSEcCtD
Alosetron—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.000195	0.00581	CbGpPWpGaD
Alosetron—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000194	0.00134	CcSEcCtD
Alosetron—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000194	0.00134	CcSEcCtD
Alosetron—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000191	0.00132	CcSEcCtD
Alosetron—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.00019	0.00132	CcSEcCtD
Alosetron—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000189	0.0013	CcSEcCtD
Alosetron—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000188	0.0013	CcSEcCtD
Alosetron—CYP2E1—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000188	0.00561	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—GCLC—chronic obstructive pulmonary disease	0.000185	0.00552	CbGpPWpGaD
Alosetron—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000185	0.00551	CbGpPWpGaD
Alosetron—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000184	0.00127	CcSEcCtD
Alosetron—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000183	0.00127	CcSEcCtD
Alosetron—CYP1A2—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000174	0.0052	CbGpPWpGaD
Alosetron—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000172	0.00119	CcSEcCtD
Alosetron—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000172	0.00119	CcSEcCtD
Alosetron—Rash—Formoterol—chronic obstructive pulmonary disease	0.000171	0.00118	CcSEcCtD
Alosetron—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000171	0.00118	CcSEcCtD
Alosetron—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00118	CcSEcCtD
Alosetron—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00118	CcSEcCtD
Alosetron—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00017	0.00508	CbGpPWpGaD
Alosetron—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.00017	0.00507	CbGpPWpGaD
Alosetron—Headache—Formoterol—chronic obstructive pulmonary disease	0.00017	0.00117	CcSEcCtD
Alosetron—Headache—Arformoterol—chronic obstructive pulmonary disease	0.00017	0.00117	CcSEcCtD
Alosetron—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000169	0.00506	CbGpPWpGaD
Alosetron—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000169	0.00117	CcSEcCtD
Alosetron—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000169	0.00117	CcSEcCtD
Alosetron—Rash—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00116	CcSEcCtD
Alosetron—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000167	0.00116	CcSEcCtD
Alosetron—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000167	0.00115	CcSEcCtD
Alosetron—Depression—Prednisone—chronic obstructive pulmonary disease	0.000166	0.00115	CcSEcCtD
Alosetron—Headache—Montelukast—chronic obstructive pulmonary disease	0.000166	0.00115	CcSEcCtD
Alosetron—CYP1A2—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000163	0.00488	CbGpPWpGaD
Alosetron—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000163	0.00487	CbGpPWpGaD
Alosetron—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000162	0.00112	CcSEcCtD
Alosetron—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000162	0.00112	CcSEcCtD
Alosetron—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00111	CcSEcCtD
Alosetron—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000161	0.00111	CcSEcCtD
Alosetron—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000161	0.00111	CcSEcCtD
Alosetron—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000161	0.00111	CcSEcCtD
Alosetron—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00111	CcSEcCtD
Alosetron—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000157	0.00109	CcSEcCtD
Alosetron—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000155	0.00107	CcSEcCtD
Alosetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000153	0.00456	CbGpPWpGaD
Alosetron—CYP2E1—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000152	0.00453	CbGpPWpGaD
Alosetron—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000152	0.00105	CcSEcCtD
Alosetron—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000151	0.00105	CcSEcCtD
Alosetron—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000151	0.00104	CcSEcCtD
Alosetron—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.00015	0.00449	CbGpPWpGaD
Alosetron—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.00015	0.00104	CcSEcCtD
Alosetron—CYP2E1—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.00015	0.00447	CbGpPWpGaD
Alosetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000147	0.00439	CbGpPWpGaD
Alosetron—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00433	CbGpPWpGaD
Alosetron—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000142	0.00098	CcSEcCtD
Alosetron—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000926	CcSEcCtD
Alosetron—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000916	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.00013	0.00388	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000128	0.00384	CbGpPWpGaD
Alosetron—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000125	0.000867	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000125	0.00372	CbGpPWpGaD
Alosetron—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000124	0.00369	CbGpPWpGaD
Alosetron—CYP2E1—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000123	0.00368	CbGpPWpGaD
Alosetron—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000121	0.000838	CcSEcCtD
Alosetron—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000121	0.000836	CcSEcCtD
Alosetron—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.00012	0.00358	CbGpPWpGaD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000119	0.00356	CbGpPWpGaD
Alosetron—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000118	0.000814	CcSEcCtD
Alosetron—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000116	0.000805	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—CYP1A1—chronic obstructive pulmonary disease	0.000113	0.00337	CbGpPWpGaD
Alosetron—CYP1A2—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000113	0.00337	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1A1—chronic obstructive pulmonary disease	0.000113	0.00337	CbGpPWpGaD
Alosetron—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000779	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTT1—chronic obstructive pulmonary disease	0.000111	0.00332	CbGpPWpGaD
Alosetron—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000769	CcSEcCtD
Alosetron—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000766	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GCLC—chronic obstructive pulmonary disease	0.00011	0.00328	CbGpPWpGaD
Alosetron—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.00011	0.000759	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000108	0.00323	CbGpPWpGaD
Alosetron—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000108	0.000747	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000107	0.0032	CbGpPWpGaD
Alosetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000107	0.00319	CbGpPWpGaD
Alosetron—Infection—Prednisone—chronic obstructive pulmonary disease	0.000106	0.000732	CcSEcCtD
Alosetron—CYP1A2—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000106	0.00315	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000106	0.00315	CbGpPWpGaD
Alosetron—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00315	CbGpPWpGaD
Alosetron—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000716	CcSEcCtD
Alosetron—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000103	0.000712	CcSEcCtD
Alosetron—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	9.91e-05	0.00296	CbGpPWpGaD
Alosetron—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	9.7e-05	0.000671	CcSEcCtD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	9.69e-05	0.0029	CbGpPWpGaD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	9.57e-05	0.00286	CbGpPWpGaD
Alosetron—Rash—Prednisolone—chronic obstructive pulmonary disease	9.24e-05	0.000639	CcSEcCtD
Alosetron—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.23e-05	0.000639	CcSEcCtD
Alosetron—Fatigue—Prednisone—chronic obstructive pulmonary disease	9.18e-05	0.000635	CcSEcCtD
Alosetron—Headache—Prednisolone—chronic obstructive pulmonary disease	9.18e-05	0.000635	CcSEcCtD
Alosetron—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	9.13e-05	0.00273	CbGpPWpGaD
Alosetron—Constipation—Prednisone—chronic obstructive pulmonary disease	9.11e-05	0.00063	CcSEcCtD
Alosetron—HTR3A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	9.04e-05	0.0027	CbGpPWpGaD
Alosetron—CYP1A2—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	9.01e-05	0.00269	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9e-05	0.00269	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	8.87e-05	0.00265	CbGpPWpGaD
Alosetron—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.78e-05	0.000607	CcSEcCtD
Alosetron—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	8.71e-05	0.0026	CbGpPWpGaD
Alosetron—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.7e-05	0.000602	CcSEcCtD
Alosetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.66e-05	0.00259	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	8.61e-05	0.00257	CbGpPWpGaD
Alosetron—Urticaria—Prednisone—chronic obstructive pulmonary disease	8.46e-05	0.000585	CcSEcCtD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	7.86e-05	0.00235	CbGpPWpGaD
Alosetron—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.85e-05	0.000543	CcSEcCtD
Alosetron—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	7.71e-05	0.0023	CbGpPWpGaD
Alosetron—Asthenia—Prednisone—chronic obstructive pulmonary disease	7.64e-05	0.000529	CcSEcCtD
Alosetron—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.62e-05	0.00227	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.53e-05	0.00225	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.5e-05	0.00224	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.4e-05	0.00221	CbGpPWpGaD
Alosetron—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	7.4e-05	0.00221	CbGpPWpGaD
Alosetron—HTR3A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	7.3e-05	0.00218	CbGpPWpGaD
Alosetron—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	7.09e-05	0.00212	CbGpPWpGaD
Alosetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	7.04e-05	0.0021	CbGpPWpGaD
Alosetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	6.95e-05	0.00208	CbGpPWpGaD
Alosetron—CYP2E1—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	6.9e-05	0.00206	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	6.8e-05	0.00203	CbGpPWpGaD
Alosetron—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.77e-05	0.000468	CcSEcCtD
Alosetron—Rash—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000465	CcSEcCtD
Alosetron—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.71e-05	0.000464	CcSEcCtD
Alosetron—Headache—Prednisone—chronic obstructive pulmonary disease	6.67e-05	0.000462	CcSEcCtD
Alosetron—CYP2E1—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.54e-05	0.00195	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	6.51e-05	0.00194	CbGpPWpGaD
Alosetron—CYP2E1—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.45e-05	0.00193	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	6.43e-05	0.00192	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.33e-05	0.00189	CbGpPWpGaD
Alosetron—Nausea—Prednisone—chronic obstructive pulmonary disease	6.33e-05	0.000438	CcSEcCtD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	6.25e-05	0.00187	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.24e-05	0.00186	CbGpPWpGaD
Alosetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	5.71e-05	0.00171	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	5.35e-05	0.0016	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	5.29e-05	0.00158	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.28e-05	0.00158	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—APIP—chronic obstructive pulmonary disease	5.26e-05	0.00157	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.21e-05	0.00156	CbGpPWpGaD
Alosetron—HTR3A—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	5.17e-05	0.00154	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	5.02e-05	0.0015	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	4.96e-05	0.00148	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	4.85e-05	0.00145	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.85e-05	0.00145	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.78e-05	0.00143	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	4.76e-05	0.00142	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	4.76e-05	0.00142	CbGpPWpGaD
Alosetron—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.6e-05	0.00137	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	4.57e-05	0.00137	CbGpPWpGaD
Alosetron—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.54e-05	0.00135	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	4.53e-05	0.00135	CbGpPWpGaD
Alosetron—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	4.53e-05	0.00135	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	4.51e-05	0.00135	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	4.45e-05	0.00133	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	4.17e-05	0.00125	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.15e-05	0.00124	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	4.12e-05	0.00123	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.09e-05	0.00122	CbGpPWpGaD
Alosetron—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.93e-05	0.00117	CbGpPWpGaD
Alosetron—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	3.88e-05	0.00116	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	3.7e-05	0.00111	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.48e-05	0.00104	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	3.48e-05	0.00104	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	3.43e-05	0.00103	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GC—chronic obstructive pulmonary disease	3.39e-05	0.00101	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	3.2e-05	0.000956	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	3.16e-05	0.000944	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	3.16e-05	0.000942	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.15e-05	0.000941	CbGpPWpGaD
Alosetron—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	3.03e-05	0.000906	CbGpPWpGaD
Alosetron—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	2.99e-05	0.000893	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.64e-05	0.000788	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.45e-05	0.000732	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	2.44e-05	0.000729	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	2.43e-05	0.000726	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	2.38e-05	0.000712	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	2.25e-05	0.000673	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.22e-05	0.000662	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.09e-05	0.000626	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	2.04e-05	0.000609	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.89e-05	0.000566	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.85e-05	0.000553	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GCLC—chronic obstructive pulmonary disease	1.83e-05	0.000547	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.77e-05	0.000527	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CTGF—chronic obstructive pulmonary disease	1.67e-05	0.000499	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.62e-05	0.000483	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	1.57e-05	0.00047	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.54e-05	0.00046	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	1.51e-05	0.000451	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.46e-05	0.000437	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.3e-05	0.000389	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.29e-05	0.000385	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.28e-05	0.000383	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.27e-05	0.000378	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.2e-05	0.000359	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.18e-05	0.000352	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.17e-05	0.000351	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.12e-05	0.000334	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.11e-05	0.000332	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.1e-05	0.000329	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.08e-05	0.000323	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.03e-05	0.000306	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1e-05	0.0003	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	9.03e-06	0.00027	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.9e-06	0.000266	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	8.59e-06	0.000257	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	8.49e-06	0.000254	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.3e-06	0.000248	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.86e-06	0.000235	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	7.75e-06	0.000231	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.71e-06	0.00023	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.61e-06	0.000227	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—ALB—chronic obstructive pulmonary disease	7.6e-06	0.000227	CbGpPWpGaD
Alosetron—CYP2E1—Metabolism—NOS3—chronic obstructive pulmonary disease	7.27e-06	0.000217	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	7.14e-06	0.000213	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	7.09e-06	0.000212	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.72e-06	0.000201	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	5.95e-06	0.000178	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	5.87e-06	0.000175	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	5.47e-06	0.000163	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	5.35e-06	0.00016	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	5.19e-06	0.000155	CbGpPWpGaD
Alosetron—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	5.11e-06	0.000153	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	4.57e-06	0.000136	CbGpPWpGaD
Alosetron—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	4.37e-06	0.000131	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	3.53e-06	0.000105	CbGpPWpGaD
Alosetron—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	3.37e-06	0.000101	CbGpPWpGaD
